Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/718,703external-prioritypatent/US5824662A/en
Priority claimed from US08/775,586external-prioritypatent/US5795877A/en
Priority claimed from US08/778,733external-prioritypatent/US5863536A/en
Priority claimed from US08/825,997external-prioritypatent/US5962521A/en
Priority claimed from US08/835,572external-prioritypatent/US5902817A/en
Priority claimed from US08/842,360external-prioritypatent/US6054444A/en
Priority claimed from US08/863,624external-prioritypatent/US6046180A/en
Priority claimed from US08/858,985external-prioritypatent/US6025344A/en
Priority claimed from US08/884,479external-prioritypatent/US6017903A/en
Priority claimed from US08/899,319external-prioritypatent/US5977090A/en
Application filed by Guilford Pharm IncfiledCriticalGuilford Pharm Inc
Publication of AR010987A1publicationCriticalpatent/AR010987A1/es
Optisk aktiv 2-aminotetralin, fremgangsmåde til dets fremstilling og farmaceutiske præparater indeholdende selv samme, effektiv til forebyggelse og behandling af septisk chok